Navigation Links
Genzyme/ACMG Foundation Genetics Training Award in Clinical Biochemical Genetics announced
Date:4/5/2012

Carlos E. Prada, MD of Cincinnati Children's Hospital and James D. Weisfeld-Adams, MD of Mount Sinai School of Medicine, NY were honored as the 2012-2013 recipients of the Genzyme/ACMG Foundation Medical Genetics Training Award in Clinical Biochemical Genetics at the ACMG 2012 Annual Clinical Genetics Meeting in Charlotte, NC.

The objective of the two Genzyme/ACMG Foundation Awards is to support a national training program to encourage the recruitment and training of clinicians in the field of clinical biochemical genetics and especially in the diagnosis, management and treatment of individuals with metabolic diseases. For the first time, two awardees will be given the opportunity to participate in an in-depth clinical experience at a premier medical center with expertise and significant clinical volume in the area of biochemical genetics.

The Award grants $75,000 per year to each of two recipients selected by the ACMG Foundation through a competitive process and will provide for the sponsorship of one year of the trainees' clinical genetics subspecialty in biochemical genetics following residency.

Dr. Prada is currently undertaking a combined residency/fellowship in Pediatrics and Genetics at Cincinnati Children's Hospital Medical Center. He said, "I am very interested in clinical research of lysosomal diseases. The goal of my proposed research is to characterize imaging and serum biomarkers in individuals with MPSs with the future goal of identifying individuals at risk for cardiovascular complications and early initiation of therapies to improve outcomes." Dr. Prada completed his Doctor of Medicine at Universidad Industrial de Santander in Colombia and a Postdoctoral Research Fellowship in Cancer Research at University of California, San Diego.

The second award recipient, Dr. Weisfeld-Adams, received his medical degree from the University of Aberdeen in Scotland, and postgraduate training at the Royal Hospital for Sick Children in Glasgow, Scotland. More recently, he completed a combined residency/fellowship in Pediatrics and Medical Genetics at Mount Sinai School of Medicine in New York, and has recently been appointed to the clinical faculty at Mount Sinai. His research focuses on combined methylmalonic aciduria and homocystinuria, cbl C type (cobalamin C disease). His research aims to characterize the neuropathology of this disease, focusing in particular in the role of oxidative injury, disordered myelin biology, and hyperhomocysteinemia. An animal model of the disorder is under development, and, in a multidisciplinary collaboration with several other investigators, Dr. Weisfeld-Adams has initiated a clinical natural history study evaluating various aspects of the neurologic phenotype in a cohort of children and adults with this disease.

"The Genzyme/ACMG Foundation Clinical Genetics Award in Clinical Biochemical Genetics is critical to the development of the genetics workforce. Through this financial award we are supporting the education of those who are working to advance biochemical research and to develop new standards of practice in medical genetics in the United States which will both improve health and save lives," said R. Rodney Howell, MD, FACMG, president of the ACMG Foundation.

Since 2005, the Genzyme Corporation has generously sponsored this prestigious award, and last year they doubled their commitment for the 2012 through 2016 Fellowships. The ACMG Foundation is honored to have the Genzyme Corporation as a member of its Corporate Partners Program. For more information about the Corporate Partners Program and other ways to support the work of the ACMG Foundation, please visit www.acmgfoundation.org.


'/>"/>

Contact: Kathy Ridgely Beal
kbeal@acmg.net
301-238-4582
American College of Medical Genetics
Source:Eurekalert

Related biology news :

1. Margarita Saenz, M.D. is recipient of Genzyme/ACMGF Fellowship in Biochemical Genetics
2. Ayman El-Hattab, MD is awarded the 2010 Genzyme/ACMG Foundation Genetics Fellowship
3. A major prize in the chemical sciences announced by the Camille and Henry Dreyfus Foundation
4. Entertainment Software Association Foundation awards grant to FAS for immune attack
5. National Science Foundation grants Clemson professors award to develop nanoprobes
6. Dunn Foundation gives Rice $3M for collaborative research grants
7. National Science Foundation grant expands UMCES oyster research
8. UT Southwestern researcher awarded Gates Foundation grant for novel vaccine development
9. The Camille & Henry Dreyfus Foundation to host important symposium on chemistry and the environment
10. Parkinsons Disease Foundation announces award of $150,000
11. Meyskens honored with AACR-Prevent Cancer Foundation award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
(Date:4/14/2016)... TEL AVIV, Israel , April 14, 2016 /PRNewswire/ ... in Behavioral Authentication and Malware Detection, today announced the ... has already assumed the new role. Goldwerger,s ... for BioCatch, on the heels of the deployment of ... In addition, BioCatch,s behavioral biometric technology, which discerns unique ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... today announced the launch of the Supplyframe Design Lab . Located in ... to explore the future of how hardware projects are designed, built and brought ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... YORK , June 23, 2016 ... trading session at 4,833.32, down 0.22%; the Dow Jones Industrial ... S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), ... Therapeutics Inc. (NASDAQ: BIND ). Learn more about ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of intelligent tools designed, tuned and optimized exclusively for Okuma CNC machining centers ... The result of a collaboration among several companies with expertise in toolholding, cutting ...
Breaking Biology Technology: